April 30 (Reuters) - Mesoblast Ltd MSB.AX :
* ANNOUNCED 60 DAY RESULTS FROM RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L IN 222 VENTILATOR-DEPENDENT COVID-19 PATIENTS
* REMESTEMCEL-L REDUCED MORTALITY THROUGH DAY 60 BY 46% IN PATIENTS WITH MODERATE/SEVERE ARDS BELOW AGE 65, BUT NOT IN PATIENTS 65 OR OLDER